Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

ABSTRACT:

Background

The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown.

Methods

At 89 clinical sites, we randomly assigned 660 adults (mean age, 61±10 years) with diabetic macular edema involving the macular center to receive intravitreous aflibercept at a dose of 2.0 mg (224 participants), bevacizumab at a dose of 1.25 mg (218 participants), or ranibizumab at a dose of 0.3 mg (218 participants). The study drugs were administered as often as every 4 weeks, according to a protocol-specified algorithm. The primary outcome was the mean change in visual acuity at 1 year.

Results

From baseline to 1 year, the mean visual-acuity letter score (range, 0 to 100, with higher scores indicating

SUBMITTER: Diabetic Retinopathy Clinical Research Network 

PROVIDER: S-EPMC4422053 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature